NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong are investigating the Board of Directors of Cephalon, Inc. (Nasdaq: CEPH) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA). Under the terms of the proposed deal, Cephalon shareholders will receive $81.50 per share in cash for a total enterprise value of approximately $6.8 billion.
The investigation concerns whether the Cephalon Board of Directors breached their fiduciary duties to Cephalon stockholders by failing to adequately shop the Company before entering into this transaction and whether Teva Pharmaceutical Industries Ltd. is underpaying for Cephalon shares. According to Thomson/First Call, at least one analyst placed a price target for Cephalon stock at $92 per share.
If you own common stock in Cephalon and wish to obtain additional information, please contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.584.2740, or visit http://www.wongesq.com/cephalon.html.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.